Scarica l'app Stockscreener
45.10
0.53%
0.24
Precedente Chiudi:
$44.86
Aprire:
$45.01
Volume 24 ore:
2.45M
Relative Volume:
1.80
Capitalizzazione di mercato:
$3.15B
Reddito:
-
Utile/perdita netta:
$-98.78M
Rapporto P/E:
-27.11
EPS:
-1.6638
Flusso di cassa netto:
$-65.60M
1 W Prestazione:
+11.74%
1M Prestazione:
+13.80%
6M Prestazione:
+170.38%
1 anno Prestazione:
+109.09%
Intervallo 1D:
$44.22
$45.72
Intervallo di 1 settimana:
$39.00
$47.36
Portata 52W:
$14.79
$48.53
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
45.10 | 3.15B | 0 | -98.78M | -65.60M | -1.6638 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Goldman | Buy |
| 2024-12-13 | Iniziato | BTIG Research | Buy |
| 2024-09-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-09 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | Jefferies | Buy |
Mostra tutto
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Enliven Therapeutics Closes $460 Million Upsized Public Offering - Global Legal Chronicle
Hedge Fund and Insider Trading News: John Paulson, Warren Buffett, Ray Dalio, Brevan Howard, Rokos Capital Management, Noble Corp PLC (NE), Enliven Therapeutics Inc (ELVN), and More - Insider Monkey
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development - Stocktwits
Enliven Therapeutics Inc (ELVN) Institutional Confidence - TradingKey
Enliven Therapeutics Inc (ELVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enliven Therapeutics Inc (ELVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enliven Therapeutics Inc (ELVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enliven Therapeutics Inc (ELVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Orbimed sells $12.7m in Enliven Therapeutics stock By Investing.com - Investing.com Nigeria
Enliven Therapeutics(ELVN.US) 10% Shareholder Sells US$12.67 Million in Common Stock - Moomoo
OrbiMed funds trim Enliven Therapeutics (ELVN) stake with 281,408-share sale - Stock Titan
OrbiMed, Enliven Therapeutics (ELVN) stake now 7.63M shares - Stock Titan
Enliven Therapeutics Inc (ELVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Enliven Therapeutics Inc (ELVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Enliven Therapeutics Inc (ELVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enliven Therapeutics moves HQ from Boulder to California - BizWest
Enliven Therapeutics (ELVN) affiliate notifies broker to offer 18,054 shares - Stock Titan
Ex-Genentech exec moves Boulder biotech to Bay Area with $400 million in the bank - The Business Journals
Former Genentech exec moves company to Bay Area from Colorado with $400 million in the bank - The Business Journals
Enliven Therapeutics, Inc. (ELVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Enliven Therapeutics Inc (ELVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enliven Therapeutics, Inc. (ELVN) stock price, news, quote and history - Yahoo Finance Singapore
[144] Enliven Therapeutics, Inc. SEC Filing - Stock Titan
What Does Enliven Therapeutics’ Rule 144 Filing Mean For Investors? - Kalkine Media
Enliven Therapeutics closes $460M public offering - Investing.com UK
Enliven Therapeutics, Inc. (ELVN) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
Enliven Therapeutics closes $460M public offering By Investing.com - Investing.com Nigeria
Enliven Therapeutics Closes Upsized $460 Million Public Offering - marketscreener.com
Biotech Enliven just raised $460M in stock and warrants - Stock Titan
Responsive Playbooks and the ELVN Inflection - Stock Traders Daily
Enliven Therapeutics reports positive phase 1 CML data and FDA alignment for phase 3 trial (ELVN) - MSN
Stifel Initiates Enliven Therapeutics at Buy With $60 Price Target - Moomoo
Enliven Therapeutics Prices $400 Million Public Offering - Moomoo
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating - Moomoo
Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial - Insider Monkey
5 Stocks That Absolutely Exploded Higher - Insider Monkey
Why Is Enliven Therapeutics Stock (ELVN) Up Today? - TipRanks
ELVN Stock Jumps As FDA-Cleared Path Fuels Phase 3 Push - timothysykes.com
Enliven Therapeutics Prices ~$376 Million Equity Offering; Jefferies, Goldman, Morgan Stanley Lead - TradingView
Enliven Therapeutics (Nasdaq: ELVN) plans $400M stock and warrant sale - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) raises $376M via 8.93M-share offering - Stock Titan
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise - StocksToTrade
Enliven (ELVN) Sees Significant Price Increase - GuruFocus
ELVN Stock Jumps As FDA Clears Path For Phase 3 ENABLE Trial - StocksToTrade
Enliven Therapeutics Inc. (NASDAQ: ELVN) Share Price, ELVN Stock News, ELVN Share Price & Updates - Kalkine
Enliven Therapeutics (ELVN) Stock Surges On FDA, Trial Wins - timothysykes.com
Enliven Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants - MSN
Key facts: Enliven posts ELVN-001 Phase 1 data; files $250M offering - TradingView
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid LeukemiaSlideshow (NASDAQ:ELVN) 2026-06-12 - Seeking Alpha
Enliven Therapeutics prices $400M public offering at $37.50 - Investing.com UK
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):